Claritev Corporation reported $995M of revenue over the trailing twelve months, +6.3% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $995M (to Q2 2026). Net income: −$283M, trailing twelve months to Q2 2026. Free cash flow: −$18M, trailing twelve months to Q2 2026. Operating margin: 3.2%, trailing twelve months to Q2 2026.

CTEVClaritev Corporation

Healthcare

$24.38-56% 1Y

$24.38

$13.4752 weeks$71.36

CTEV as reported

Claritev Corporation reported $995M of revenue over the trailing twelve months, +6.3% on the year before. 11 reported series are charted on this page, each one as filed.

$995M

Revenue, trailing twelve months · to Q2 2026 · +6.3% against the twelve months before

Net income: −$283M
Net income · −57% year on year · trailing twelve months to Q2 2026
Free cash flow: −$18M
Free cash flow · −67% year on year · trailing twelve months to Q2 2026
Operating margin: 3.2%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CTEV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$995M	+6.3%	Q2 2026
Net income	−$283M	−57%	Q2 2026
EPS	−$17.01	−58%	Q2 2026
Gross margin	73%	n/a	Q2 2026
Operating margin	3.2%	n/a	Q2 2026
Net margin	−29%	n/a	Q2 2026
ROE	178%	n/a	Q2 2026
ROA	−6.1%	n/a	Q2 2026
ROIC	0.37%	n/a	Q2 2026
Free cash flow	−$18M	−67%	Q2 2026
P/E	24.2	n/a	Q3 2022 · 15 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.